Gan & Lee Pharmaceuticals. (SHA:603087)

Market Cap	35.70B +44.1%
Revenue (ttm)	3.95B +13.7%
Net Income	1.02B +23.3%
EPS	1.73 +22.7%
Shares Out	595.20M
PE Ratio	34.63
Forward PE	23.25
Dividend	1.50 (2.54%)
Ex-Dividend Date	n/a

Volume	4,575,236
Average Volume	6,820,186
Open	59.95
Previous Close	59.98
Day's Range	59.61 - 60.50
52-Week Range	48.23 - 82.25
Beta	0.57
RSI	42.99
Earnings Date	Apr 23, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 5,245
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603087

Financial Performance

In 2025, SHA:603087's revenue was 4.05 billion, an increase of 33.06% compared to the previous year's 3.05 billion. Earnings were 1.14 billion, an increase of 86.05%.